SCHEMBL6188750

SCHEMBL6188750

CCOC(=O)COc1ccc(OC2CCN(C(=O)OC(C)(C)C)C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.54
USP30 Q70CQ3 1/20 0.49
PIK3CD O00329 5/20 0.46
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6192490 0.94 GPR119 (0.62) GPR119
SCHEMBL3911512 0.87 GPR119 (0.52) GPR119USP30PIK3CDPOLB
SCHEMBL6192471 0.87 GPR119 (0.55) GPR119USP30PIK3CD
SCHEMBL8470092 0.85 PIK3CD (0.44) GPR119USP30PIK3CD
SCHEMBL7386960 0.83 GPR119 (0.52) GPR119USP30PIK3CD
SCHEMBL7388684 0.83 GPR119 (0.52) GPR119USP30PIK3CDPOLB
SCHEMBL7389633 0.83 GPR119 (0.52) GPR119USP30PIK3CDPOLB
SCHEMBL20179924 0.83 GPR119 (0.58) GPR119USP30PIK3CD
SCHEMBL15297678 0.81 GPR119 (0.56) GPR119USP30PIK3CD
SCHEMBL1975644 0.81 PRMT5 (0.44) GPR119USP30PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1070714-A9 AMIDINE COMPOUNDS JAPAN TOBACCO INC. (JP) 2005-10-19 EP disclosed
US-20040006099-A1 Amidine compounds JAPAN TOBACCO INC. 2004-01-08 US disclosed
US-6562828-B1 Novel amidine compound having a blood coagulation factor Xa inhibitory activity JAPAN TOBACCO INC. (JP) 2003-05-13 US disclosed
EP-1070714-A1 AMIDINE COMPOUNDS JAPAN TOBACCO INC. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006099-A1 Amidine compounds F2, SERPINC1, F12 GPR119 2900/4885USP30 4217/4885PIK3CD 3909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.